Global NGS Solution for Early Cancer Screening Market Growth (Status and Outlook) 2025-2031

According to this study, the global NGS Solution for Early Cancer Screening market size will reach US$ 1391 million by 2031.

There are nearly 20 million new cancer cases and nearly 10 million cancer deaths worldwide each year, and the cancer prevalence in my country is at an internationally medium-to-high level. WHO believes that one-third of cancers can be cured through early detection. Compared with advanced cancer, early cancer has not metastasized and is easier to be eliminated through surgery, radiotherapy, chemotherapy and other means. Treatment intervention in the early stages of cancer can help increase the patient's chance of survival, reduce pain and reduce economic burden. At present, there is no effective means to treat advanced cancer. Early detection and early treatment are considered to be the most effective means of treating cancer. Therefore, improving the sensitivity of tumor detection is of great significance to improving the survival rate of cancer patients, among which early screening and early diagnosis will play an important role.

There are two main technical routes for early screening products in NGS. One is cfDNA methylation sequencing based on gene methylation characteristics, and the other is whole genome sequencing based on cfDNA fragmentation end characteristics and CNV. Methylation-based NGS technology can usually be divided into capture method or multiple PCR to obtain the target area through machine learning and model analysis to obtain early tumor weak signals. Detection based on cfDNA fragmentation end characteristics and CNV is usually based on different types of genome library construction, and AI algorithm analysis is performed on markers to capture the differences in early weak signals of tumors.

United States market for NGS Solution for Early Cancer Screening is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for NGS Solution for Early Cancer Screening is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for NGS Solution for Early Cancer Screening is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key NGS Solution for Early Cancer Screening players cover GRAIL, Exact Sciences, Guardanthealth, Akery, Foundation Medicine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “NGS Solution for Early Cancer Screening Industry Forecast” looks at past sales and reviews total world NGS Solution for Early Cancer Screening sales in 2024, providing a comprehensive analysis by region and market sector of projected NGS Solution for Early Cancer Screening sales for 2025 through 2031. With NGS Solution for Early Cancer Screening sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world NGS Solution for Early Cancer Screening industry.

This Insight Report provides a comprehensive analysis of the global NGS Solution for Early Cancer Screening landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on NGS Solution for Early Cancer Screening portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global NGS Solution for Early Cancer Screening market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NGS Solution for Early Cancer Screening and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NGS Solution for Early Cancer Screening.

This report presents a comprehensive overview, market shares, and growth opportunities of NGS Solution for Early Cancer Screening market by product type, application, key players and key regions and countries.

Segmentation by Type:
cfDNA Methylation Sequencing
Whole Genome Sequencing Based On cfDNA Fragmentation End Characteristics and CNV

Segmentation by Application:
Hospitals
Clinics
Medical Laboratories
University Laboratories
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GRAIL
Exact Sciences
Guardanthealth
Akery
Foundation Medicine
Illumina, Inc.
Hangzhou New Horizon Health Technology Co., Ltd.
Berry Oncology Co., Ltd.
Genetron Health (Beijing) Co., Ltd.
Yeasen
Guangzhou Burning Rock Dx Co., Ltd.
BGI Genomics Co., Ltd.
Jiangsu Huayuan Biotechnology Co., Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver. Show more